Laboratory Abnormalities in RESIST Trials

Incidence of laboratory abnormalities

Treatment-Emergent Laboratory Abnormalities Reported in ≥2% of Adult Patients (48-Week Analysis)

ALT and/or AST, cholesterol, and triglyceride levels

• Significantly greater elevations in ALT and/or AST, cholesterol, and triglyceride levels were observed in patients treated with APTIVUS/r vs CPI/r
• In controlled clinical trials extending up to 96 weeks, the proportion of patients who developed Grade 2-4 ALT and/or AST elevations increased from 26% at week 48 to 32.1% at week 96 with APTIVUS/r
• The risk of developing transaminases elevations is greater during the first year of therapy